The efficacy and safety of granisetron and ondansetron for the prophylaxis of nausea and vomiting resulting from hyperfractionated total body irradiation (TBI) were assessed. Thirty-four patients randomly received double-blind, oral granisetron (2 mg, 1 h before first daily fraction of radiation) or ondansetron (8 mg, 1.5 h prior to each fraction of TBI). Ninety patients who received the same TBI regimen prior to bone marrow transplantation (BMT), but no 5-HT 3 -receptor antagonist, were identified and comprised the historical control group. By design, this study was only powered to show a difference between each of the active treatment groups and the historical control group. Significantly more patients given granisetron (33.3%) or ondansetron (26.7%) had zero emetic episodes over 4 days, the primary efficacy end point, than those in the historical control group (0%) (P Ͻ 0.01; intent-to-treat). Secondary efficacy end points were also evaluated. During the first 24 h, significantly more patients taking granisetron (61.1%) or ondansetron (46.7%) had zero emetic episodes than patients in the historical control group (6.7%) (P Ͻ 0.01). Complete emetic control (no emesis or rescue antiemetic) over 4 days was more frequent in patients taking granisetron (27.8%) or ondansetron (26.7%) compared with the historical control group (0%) (P Ͻ 0.01). Significantly fewer patients taking granisetron (18/18), but not those taking ondansetron (12/15), experienced more than five emetic episodes during the 4 days of the study compared with the historical control group (40/90; P Ͻ 0.01). Oral granisetron and ondansetron are safe and effective for the prevention of nausea and vomiting resulting from TBI. Bone Marrow Transplantation (2000) 26, 203-210.
There have been many advances in the treatment of patients with malignant diseases requiring total body irradiation (TBI) prior to bone marrow transplantation (BMT). [1] [2] [3] These advances have allowed more patients to successfully receive TBI and BMT while also decreasing morbidity and mortality resulting from treatment complications. [2] [3] [4] Nausea and vomiting are still major problems with TBI. In response to radiation, serotonin is released from enterochromaffin cells in the gastrointestinal (GI) mucosa. [5] [6] [7] Serotonin interacts with the 5-HT 3 receptors on vagal afferent neurons and the chemoreceptor trigger zone, which elicits nausea and vomiting. 8 The specific emetogenic potential of TBI is difficult to evaluate because TBI is used often in combination with or after emetogenic chemotherapy and many different TBI regimens are used in clinical practice. Nevertheless, nausea and vomiting are experienced by almost all patients who receive more than 12 Gy of unfractionated irradiation. 4 Emesis was, in fact, universal among patients administered conventional antiemetic regimens who received TBI in an identical dose and schedule to that utilized in this study. 9 Conventional medications that have been used to prevent nausea and vomiting resulting from TBI given prior to BMT (eg sedating antihistamines, dopamine antagonists, phenothiazines, corticosteroids, and benzodiazepines) are not optimally effective and are associated with significant adverse effects. [10] [11] [12] [13] [14] [15] [16] [17] Granisetron and ondansetron, when given intravenously (i.v.), have been proven to be more effective than placebo and other active agents in preventing nausea and vomiting induced by highly emetogenic chemotherapy. 11, 12, [18] [19] [20] [21] Oral administration of a 5-HT 3 -receptor antagonist such as granisetron or ondansetron not only allows the medication to be absorbed so it can act peripherally and in the central nervous system, but also allows the medication to act locally in the gut to inhibit the emetogenic stimulus. The advantages of oral administration of antiemetic medications are clear: reduced costs compared to i.v. administered medication and increased ease of administration that may allow for the use of these medications in the outpatient setting. Ondansetron administered orally has been shown to be effective for the prophylaxis of TBI-induced nausea and vomiting, but no studies have assessed the efficacy of oral granisetron in adult patients for this purpose. 22 This randomized, double-blind, double-dummy trial was designed to assess the efficacy and safety of two 5-HT 3 -receptor antagonists, granisetron and ondansetron, when administered orally for the prevention of nausea and vomiting in patients receiving TBI prior to BMT compared with a prospectively defined historical negative control group composed of patients who did not receive 5-HT 3 -receptor antagonist antiemetic therapy.
Materials and methods

Patients
Thirty-six adult patients (у18 years of age) from three United States' medical centers were screened for entry; 34 met study criteria and were included in this two-arm study. The protocol was approved by the Institutional Review Board at each site. Patients gave written informed consent to participate. All patients had a diagnosis of either malignant disease or aplastic anemia, and were hospitalized to receive 11 fractions each of 120 cGy of radiation over the course of 4 days for a total radiation exposure of 1320 cGy prior to BMT and the initiation of any conditioning chemotherapy. Total body irradiation was administered prior to the initiation of conditioning chemotherapy. The fractions of radiation were given from a 10-MeV linear accelerator. On day 0 to day 1, the chest wall was blocked during the administration of radiation to protect the lungs. The block was removed for fractions given on days 2 and 3 to allow for radiation of the ribs and soft tissue underlying the lungs.
Females of childbearing potential were required to have a negative serum or urine hCG pregnancy test and had to continue using adequate contraception during the study. Males had to be either surgically sterilized or practising adequate contraception throughout the study. Baseline evaluations were made of all patients and included demographics, medical history, physical examination, vital signs, Karnofsky performance status, and prior and concomitant medications.
Excluded from the study were patients with a Karnofsky performance status score below 60, those who had received an investigational new drug within 30 days or five halflives of the medication, received conditioning or intrathecal chemotherapy within 24 h of first dose of TBI, received emetogenic systemic or intrathecal chemotherapy during the study, or who had an unstable medical disorder or primary or secondary brain neoplasm with increased intracranial pressure. Other reasons for exclusion included known hypersensitivity to any 5-HT 3 -receptor antagonist, unwillingness or inability to comply with the study protocol, or any medication with antiemetic activity taken within 24 h of receiving study medications on day 0. Those who experienced nausea within 1 h or any emesis (vomiting or retching) within 24 h of receiving study medications on day 0 were excluded from the protocol-defined population, but were included in the intent-to-treat population.
Study design
A historical control group was identified through a chart review of patients who had been treated at the City of Hope National Medical Center in Duarte, California prior to 1991. The chart review was conducted by a contracted chart reviewer who recorded the data of interest on the case report form. Excluded from the historical control group were patients who did not meet study criteria with regard to disease diagnosis, radiation regimen, age, or incomplete or missing data in the patient chart. Use of either of the study medications (granisetron or ondansetron), also excluded the patients. No other exclusion criteria applied to these patients because they were not readily available from patient charts. Ninety patients were eligible to be included in the study. Eighty-eight patients were included in the protocol-defined population; two patients who received fewer than 11 fractions of radiation were excluded.
Drug administration
Patients were randomized 1:1 to receive oral granisetron or oral ondansetron. The study medications were supplied by SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA. A round tablet containing commercially available granisetron HCl 1 mg was used in conjunction with commercially available 8-mg ondansetron tablets overencapsulated with a hard, opaque red, size 0 gelatin capsule to allow for double-blinding. Granisetron 2 mg (administered as two 1-mg tablets) was given once daily, 1 h prior to the administration of the first daily fraction of radiation. Ondansetron 8 mg was given 1.5 h prior to every fraction of radiation (three times daily for days 0 to 3 and twice daily on day 4). The doses and administration times used for both medications were the US Food and Drug Administration (FDA)-approved regimens stated in the product labeling current at the time of the study. The patients received either the study medication or a matching placebo at the scheduled administration times, 1 h prior to the first daily fraction of radiation and 1.5 h prior to each fraction of radiation (doubledummy). Patients in the historical control group did not receive prophylaxis or treatment with a 5-HT 3 -receptor antagonist. Specific antiemetic regimens were not recorded for these patients.
Patients requiring rescue antiemetic medication after receiving the first fraction of radiation were withdrawn from the study. Rescue medication of the physician's choosing was permitted if a patient experienced two or more emetic episodes between any two fractions of radiation (24-h period), a total of five or more emetic episodes during the 4 days of the study, or if the patient requested rescue antiemetic medication.
The day following the completion of the study medications, the patient's vital signs and Karnofsky performance status were assessed and adverse experiences were recorded. Women of childbearing potential were given a repeat urine or serum hCG pregnancy test.
Efficacy assessment
The primary efficacy variable was the proportion of patients who had zero emetic episodes over the 4-day study period.
Emesis was considered to be a single episode of either vomiting (expulsion of stomach contents through the mouth) or retching (an attempt to vomit that is not productive of stomach contents). A single episode of vomiting was defined as vomiting and/or retching separated by intervals of 5 min or less. The proportion of patients who had complete emetic control (no vomiting and no rescue antiemetic medication) over the 4 day study period was also assessed. Because all the patients in this study were inpatients, nurses noted when rescue medications were administered and the patients recorded efficacy data, nausea severity, and vomiting frequency in a diary.
Secondary efficacy variables included the number of emetic episodes throughout the first 24 h (day 0) and during the entire 4-day study period, the proportion of patients with no emetic episodes on day 0, and the time to first emesis. The time to first emetic episode and the number of vomiting episodes were recorded during each 24-h interval. When antiemetic rescue therapy was given in the absence of emesis, the time to rescue medication was considered to be the equivalent of time to first emesis. Also evaluated was the proportion of patients who had complete nausea control (no nausea and no rescue antiemetic medication) during the 4-day study. The maximum severity of nausea and time to first nausea were also determined. When antiemetic rescue therapy was given in the absence of nausea, time to rescue medication was considered to be the equivalent of time to first nausea.
Efficacy data for the historical control group were recorded on the case report form by the reviewer.
Safety
All adverse events, whether observed by the investigator or solicited from or volunteered by the patient, were recorded. Adverse experiences were defined as all noxious, pathologic, or unintended changes in physical signs, symptoms, or laboratory values. Included were any exacerbations of pre-existing condition or event, intercurrent illness, drug interaction, or significant worsening of the disease under investigation. Any change in study drug administration, corrective therapy given, and outcome status were documented on the case report form. Adverse experiences were elicited from the patients through standardized nonleading questions once daily during each of the 4 study days and on the day following completion of the study. In addition to those elicited by the investigators, adverse events observed by the investigators or volunteered by the patients were recorded on the case report form. Investigators judged the adverse experiences to be unrelated, probably unrelated, possibly related, or related to the study drugs. The maximum intensity of all adverse experiences was graded by the investigator as mild (easily tolerated), moderate (tolerated but interfered with daily activities), or severe (incapacitating or prevented everyday activities).
Serious adverse experiences were those that were fatal, life-threatening, disabling, or incapacitating; resulted in hospitalization or prolonged hospital stay; or were associated with congenital abnormality, cancer, or overdose (accidental or intentional). Additionally, any experience that the investigator felt was serious or suggested any sigBone Marrow Transplantation nificant hazard, contraindication, side-effect, or precaution possibly associated with the use of the drug was considered to be a serious adverse experience. For this study, any adverse events that were expected to occur as a result of hyperfractionated TBI, conditioning chemotherapy or BMT, and were not unusual in any way, were recorded on the case report form but were not recorded as serious adverse events. Events that were uncharacteristically different or unusual with regard to frequency, severity, or duration and were considered to be due to TBI, conditioning chemotherapy, or BMT were recorded as serious adverse experiences.
Statistical analysis
The target sample size was 36 randomized patients. The sample sizes of 18 patients per treatment group and 91 patients in the historical control group were calculated to provide 92% statistical power at an adjusted ␣ level of 0.01. This calculation was based on the assumption that all patients in the historical control group would experience at least one vomiting episode during the 4 days of TBI and that 30% of patients taking granisetron would be free of emesis during the 4 days. By design, the study was only powered to show a difference between each of the active treatments and the historical control group. A minimum patient population of 500 would be necessary to show a difference between the granisetron and ondansetron groups with 90% statistical power.
The primary and secondary efficacy variables were evaluated using 99% exact confidence intervals (CIs) of the difference between patients who received granisetron and the historical control group and patients who received ondansetron and the historical control group. Because 99% CIs are wider, it would therefore be more difficult to show that a difference exists; these more stringent criteria would further validate the results of this study.
The hypothesis testing of the efficacy of granisetron vs that of the medications given to patients in the historical negative control group was done in the context of the 99% CI of the difference and whether the interval included 0. The overall ␣ level was 0.02 adjusted for the two comparisons of interest. An intent-to-treat analysis was performed on the primary and secondary efficacy end points. Patients included in this analysis were randomized to one of the treatment groups, and received radiation and at least one post-dose efficacy assessment. The protocol-defined population included patients not identified as protocol violators with at least one post-dose assessment.
Results
Patients
Of 36 patients screened, 34 fitted the study criteria and were randomized to receive study medications; 18 received granisetron and 16 received ondansetron. For the historical control group, 262 patients who received fractionated TBI prior to BMT at City of Hope National Medical Center were identified from a chart review using predetermined criteria. Excluded from this group were 172 patients who did not meet study criteria with regard to radiation regimen, age, use of study medications (ondansetron or granisetron), or incomplete or missing data in the patient chart. Thus, the historical control group contained 90 patients.
There were no clinically important demographic differences between the granisetron and ondansetron treatment groups (Table 1) . Patients in the historical control group were slightly younger and weighed less than patients in the other two groups. These differences were not considered to influence the assessment of efficacy.
Primary efficacy
The protocol-defined population included six patients in the granisetron-treated group, five patients in the ondansetrontreated group, and 88 patients in the historical control group. Because of the small number of patients in the protocol-defined population, a comparative analysis of these patients was not completed. All 90 patients in the historical control group and all 18 patients randomized to receive granisetron were included in the intent-to-treat population. All patients but one receiving ondansetron were included in the intent-to-treat analysis; one patient was excluded because he never received radiation.
Ondansetron and granisetron were significantly more efficacious than the antiemetic agents used in the historical control group for the primary end point. During the 4-day study, irrespective of the use of rescue medication, no emesis occurred in 33.3% of patients taking granisetron, 26.7% of patients taking ondansetron, and 0% of patients in the historical control group (99% CI: 6.4, 69.2 for grani- setron vs historical control; 0.9, 67.3 for ondansetron vs historical control; P Ͻ 0.01) ( Table 2) . Complete emetic control, defined as no emetic episodes and no rescue antiemetic medication, occurred significantly more frequently in the active treatment groups (Table 3) . Over the course of the 4-day study, 27.8% of patients in the granisetron group and 0% of patients in the historical control group had complete emetic control (99% CI: 2.9, 64.3). During this time period, 26.7% of patients receiving ondansetron had complete emetic control (99% CI: 0.9, 67.3). Both active treatment groups experienced significantly greater efficacy than the historical control group for this variable (P Ͻ 0.01).
Secondary efficacy
The proportion of patients experiencing more than five emetic episodes over the 4 days of the study was significantly less in the granisetron group (0%; 99% CI: −71.4, −24.2; P Ͻ 0.01) vs the historical control group (55.6%). The difference between the ondansetron group (20%; 99% CI: −63.1, 1.8) and the historical control group was not significant ( Table 2) .
During day 0, 11 of 18 patients (61.1%) treated with granisetron had zero emetic episodes. In the historical control group, only six of 90 patients (6.7%) had zero emetic episodes. Four of those six patients received rescue antiemetic medication. The difference between the two groups was statistically significant (99% CI: 20.9, 84.7; P Ͻ 0.01). Seven of 15 patients (46.7%) treated with ondansetron had zero emetic episodes on day 0. Patients taking ondansetron demonstrated significantly better emetic control during the first 24 h compared with the historical control group (99% CI: 5.5, 78.0; P Ͼ 0.01).
The median time to first emesis was 36 h for the granisetron group and 15.8 h for the ondansetron group. These data were not available for the historical control group, therefore, a statistical comparison was not possible.
Complete nausea control (no nausea and no rescue antiemetic medication) throughout day 0 occurred in eight of 18 patients (44.4%) treated with granisetron whereas only two of 90 patients (2.2%) in the historical control group had complete nausea control (Table 4) . This difference was statistically significant (99% CI: 11.4, 75.9). Complete nausea control occurred in 26.7% of patients treated with ondansetron on day 0; comparison with the historical control group was not significant (99% CI: −2.6, 64.8). The difference between the historical control group and each active treatment group for the parameter of complete nausea control throughout the entire 4-day study was not statistically significant (granisetron vs control (99% CI: −5.4, 47.3) and ondansetron vs control (99% CI: −5.2, 54.5)).
From the start of the initial fraction of TBI, the first experience of nausea or use of rescue antiemetic medication was defined as the time to first nausea. This parameter was recorded for patients in both the granisetron and ondansetron treatment groups. No statistical comparison was performed because the data were not available for patients in the historical control group. The median time to first nausea for patients taking granisetron was 13 h, and the median time to first nausea for patients taking ondansetron was 13.5 h.
Safety
The most frequently reported adverse experience in both treatment groups was headache (Table 5 ). Patients treated with granisetron most frequently reported diarrhea and asthenia. The most frequently reported complaints from patients treated with ondansetron included insomnia, peripheral edema, back pain, and rash. Eleven patients reported adverse experiences that were
Bone Marrow Transplantation judged possibly related/probably unrelated to study medication: seven of 18 patients (38.9%) who received granisetron and four of 16 patients (25%) who received ondansetron. The remaining adverse events were considered to be unrelated to study medication. The severity of the adverse events was evaluated by the investigator and was determined to be mild, moderate, or severe. The investigators classified five mild, six moderate, and two severe adverse reactions in the granisetron-treated group and five mild, four moderate, and two severe adverse reactions in the ondansetron-treated group. Two patients who received granisetron reported severe headache. The Table 5 Most frequently reported adverse experiences (AEs) (overall incidence Ͼ7%) two severe adverse events in patients who received ondansetron included one severe infection and one episode of severe nervousness. Serious adverse experiences occurred in two patients in the study. One patient who received ondansetron died from a disseminated Aspergillus infection 7 days after successfully completing the study. The investigator deemed the death unrelated to study medication. Another patient developed a nonfatal irregular pulse shortly after receiving the first dose of ondansetron on day 0. The arrhythmia was ruled secondary to the patient's underlying heart disease and superimposed anxiety. This patient withdrew from the study.
Discussion
Until the advent of the selective 5-HT 3 -receptor antagonists, nausea and vomiting were the most dreaded sideeffects of cancer treatment. 20 Control of nausea and vomiting is crucial to the successful completion of TBI because patients must remain immobilized while receiving each fraction of radiation. It is also important to control nausea and vomiting, not only for the immediate nutritional and emotional support of the patient, but also because patients who have had prior exposure to emetogenic chemotherapy may experience anticipatory nausea and vomiting during subsequent treatments. 14, 18, [23] [24] [25] The efficacy of granisetron administered i.v. for prophylaxis of nausea and vomiting induced by highly emetogenic chemotherapy or irradiation has been previously evaluated. [26] [27] [28] [29] [30] [31] [32] The inadequacy of standard antiemetic regimens consisting mainly of metoclopramide is demonstrated by studies that used these regimens as the treatment for the control group and compared them with a group of patients given granisetron. 29, 31 Significantly more patients treated with granisetron had emetic control (Ͻ3 emetic episodes) in the first 24 h following the beginning of their conditioning regimens and sustained the emetic control throughout the study (87.1% and 51.0%, respectively) compared with the control group (37% and 0%, respectively; P Ͻ 0.001). 31 A complete response to the antiemetic medications during the first 24 h following fast dose rate, single fraction TBI was observed in significantly more patients treated with granisetron (53%) than those treated with a combination of metoclopramide, dexamethasone, and lorazepam (13%; P = 0.02). 29 The specific antiemetic medications and dosages administered to the patients in the historical control group were not recorded in the present study except to specify that the regimens did not include a 5-HT 3 -receptor antagonist. It can be assumed that these patients received the standard antiemetics routinely prescribed by the oncologists at the City of Hope Medical Center. As discussed previously, even in studies in which appropriate doses of conventional antiemetic medications were used, these drugs and regimens were shown to be ineffective. Therefore, regardless of which medications the patients in the historical control group received, they were ineffective and thus, constituted a negative control.
In the present study, designed to examine the efficacy of oral granisetron and oral ondansetron in parallel for prevention of nausea and vomiting in patients receiving hyperfractionated TBI prior to BMT, both 5-HT 3 -receptor antagonists were significantly more effective than the agents used in the historical control group as shown by the proportion of patients who had zero emetic episodes on day 0 and throughout the entire 4-day study. Patients taking granisetron or ondansetron also had complete emetic control significantly more frequently than patients in the historical control group during the 4 days of the study. No patients in the granisetron group had more than five emetic episodes during the entire course of the study. This was also a significant benefit of granisetron compared with the historical control group (P Ͻ 0.01).
Granisetron-treated patients had significantly better nausea control on day 0 compared with the historical control group (P Ͻ 0.01). This difference did not continue throughout the rest of the study, however, and did not occur in the ondansetron-treated group.
The results of this study correlate well with those of a previous study that compared oral ondansetron with placebo using the same TBI regimen. 22 The comparability of the results validate this study design and emphasize the significance of the findings regarding the efficacy of oral granisetron. The results of the first study show that 30% of ondansetron-treated patients experienced no vomiting episodes, whereas the results of the current study show that 26.7% of ondansetron-treated patients experienced complete emetic control. Time to first vomiting was also similar between the two trials (14.6 h vs 15.8 h). Among patients treated with ondansetron, 40% in the previous study compared with 20% in the current study experienced five or more emetic episodes.
The results in the historical control group are consistent with those in the placebo group of the previous study. 22 None of the patients in either the historical control group or the placebo group from the two studies had complete emetic control over the 4-day study period. All of the patients who received placebo or were in the historical control group required rescue antiemetic medication. This comparison emphasizes the fact that conventional antiemetic medications prior to the advent of the selective 5-HT 3 -receptor antagonists were no better than placebo. In light of these data, withholding a 5-HT 3 -receptor antagonist from a patient undergoing TBI would be unethical.
The use of a historical negative control group in this study requires particular attention because of biases that may be introduced by comparing results obtained at different times and under different conditions. Several important issues need to be addressed when considering use of a historical control group. 33 First, the historical control group must have had clearly defined criteria for patient inclusion. In this case, patients needed to have a condition that would necessitate TBI and BMT; only those receiving the specific TBI regimen used in this study were included in the historical control group to ensure that the patients were receiving the same emetogenic stimulus. The 90 patients included in the historical control group were identified through a chart review. Eighty-eight of the 90 patients received the same emetogenic stimulus as the patients in the active treatment groups. None of the patients received a 5-HT 3 -receptor antagonist prior to or during TBI, and all were treated prior to the availability of ondansetron in 1991. These were the principal considerations in selecting patients for the historical control group.
Second, historical controls were recruited earlier and possibly from a different source than the patients in the treatment groups, thus affecting the type of patient available for selection. Patients evaluated for inclusion into this study received their treatment at one of the institutions that participated in this study, the City of Hope National Medical Center. If there were a change in the criteria for selecting a patient to receive BMT, the selection would be more liberal than it had been before 1991, allowing for patients with more advanced disease to enter the current study. Liberalization could theoretically make emesis a greater problem in the patients enrolled in this study compared with those in the historical control group. Any such bias would likely make it more difficult to demonstrate efficacy of either granisetron or ondansetron compared with the historical controls.
Related to this consideration is the fact that investigators may be restrictive, either deliberately or subconsciously, when choosing patients for a new treatment. The magnitude of this concern is diminished by the fact that both agents used in this trial are commercially available, widely used, and recognized to be advances over previously available antiemetics. Investigators were therefore unlikely to be restrictive in selecting patients for entry into this study.
Third, available data for patients in the historical control group may not be the same as data collected from patients during the study. In this case, demographic information, the details of medications used, TBI administered, and the presence or absence of emesis were obtained from hospital charts and medical records. In addition, data for the patients in the historical control group were collected on the same case report form that was utilized by the investigators in this study to ensure comparable methods of data collection.
Fourth, the criteria of response may differ between the two groups of patients. However, the presence or absence of emesis is not readily subject to interpretation, and this is the only criterion of response evaluated for the historical control group.
Finally, there is a tendency to invalidate more patients on a new treatment than to invalidate historical controls. Patients on new therapy who fare badly may be excluded Bone Marrow Transplantation after subsequent inquiry reveals some protocol violation, whereas the corresponding exclusion of any historical control is made difficult because considerable time will have elapsed since they were treated. This concern was negated by conducting an intention-to-treat analysis in the current study. Therefore, the procedure in this study addresses all of the significant concerns that arise with the use of historical controls.
Because ondansetron had previously been shown to be effective for prevention of nausea and vomiting caused by hyperfractionated TBI, a negative control group, placebo or otherwise, was unethical. 12, 13, 22, 34 A trial of adequate statistical power (90%) to compare granisetron with ondansetron would require such a large patient population (at least 500 patients) that recruitment of patients and ensuring that a standardized regimen of TBI would continue to be used prior to the administration of conditioning chemotherapy would be difficult.
Thus, a prospectively defined, historical negative control group was used as a comparator against the two treatment groups. The two treatment arms allowed for randomization into an active treatment group. This allowed for doubleblinding, and created a basis for comparing the results of this study with those of a previous placebo-controlled study using the same TBI regimen to determine the efficacy of ondansetron, although it did not allow for a 'head-to-head' comparison of granisetron and ondansetron. 22 The safety of granisetron and ondansetron was demonstrated in this study. The most frequently reported adverse event in both treatment groups was headache. Diarrhea and asthenia were frequently reported by those treated with granisetron whereas those treated with ondansetron reported insomnia, peripheral edema, back pain, and rash. These adverse events were similar to those that occurred in previous studies using 5-HT 3 -receptor antagonists, further supporting the safety of these agents. 11, 20, 21 The majority of adverse experiences were judged to be either mild or moderate in severity and were considered to be possibly related/probably unrelated to study medication. Only one serious life-threatening adverse experience occurred. This patient was withdrawn from the study prior to receiving the first fraction of radiation. One death occurred 7 days after the patient was given the last dose of study medication and was considered to be unrelated to study medication.
In conclusion, oral granisetron, given as a single 2-mg dose on each day of TBI, and oral ondansetron, given as an 8-mg dose three times daily, are safe and effective for the prevention of nausea and vomiting induced by a highly emetogenic regimen of hyperfractionated TBI. Efficacy in the prevention of emesis was demonstrated over the 4-day course of TBI and especially during the first 24 h after TBI. Because complete emetic control did not occur for all patients, future studies, possibly evaluating combination drug therapy, will be necessary to optimize the antiemetic management of patients receiving TBI prior to BMT.
